Sign up USA
Proactive Investors - Run By Investors For Investors

DiaMedica says diabetic drug shows positive results in preclinical study

DiaMedica says diabetic drug shows positive results in preclinical study

DiaMedica (CVE:DMA) said Tuesday its experimental drug DM-99 for Type 1 and 2 diabetes confirmed it lowers daily insulin needs when taken with long-acting, basal insulin like Lantus.

The Winnipeg-based company said full results from the preclinical study will be published, but did not provide a date.

DiaMedica said the study revealed DM-99 alone lowers fasting glucose values in a diabetic model. 

During a tolerance test, the drug, when taken with long-acting insulin, significantly cut sugar levels immediately and well after a meal to near normal levels. 

"The results from this study suggest DM-199 co-administered with basal long-acting insulin may reduce the need for short-acting insulin around meals while improving glucose control in diabetic patients," chief executive Rick Pauls said in a statement.

"Lowering the frequency and amount of daily insulin injections and reducing the risk of hypoglycemia could significantly improve the quality of life for Type 1 diabetics and possibly for Type 2 diabetics. 

"Results are to be confirmed in future human studies."

DiaMedica is a biopharmaceutical firm focused on discovering and developing new therapies to treat diabetes and complications tied to the disease. 

The company is also developing, DM-204, a drug used to treat Type 2 diabetes. In a pre-clinical trial, the drug revealed major improvement in blood sugar control, blood pressure and cholesterol levels, it said. 

Shares in the company were trading at $1.80 on the TSX Venture Exchange. Its stock spiked to $1.94 in early morning trading.

Register here to be notified of future DMA Company articles
View full DMA profile

DiaMedica Timeline

Related Articles

March 31 2016
Amryt Pharmaceuticals is coming to the market following a reverse takeover deal with the investment firm Fastnet Equities. Here boss Joseph Wiley tells us a little bit more about the AIM newcomer.
April 13 2016
Jim Phillips, Midatech’s chief executive, said Zuplenz offers relief from some of the most debilitating side-effects of common cancer treatments. Generically called ondansetron, the oral soluble film eases the problem of gritty residue, having to wear a patch and sedative side effects of dissolving tablets and injections.
Copyright ©, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC